The CXCL10/CXCR3 axis promotes cardiac microvascular endothelial cell migration via the p38/FAK pathway in a proliferation-independent manner

Jing Bo Xia, Cheng Zhou Mao, Zhuo Ying Chen, Guang Hui Liu, Hai Yan Wu, Deng Cheng Zhou, Kyusang Park, Hui Zhao, Soo-Ki Kim, Dong Qing Cai, Xu Feng Qi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

CXCL10 is a chemokine with potent chemotactic activity for immune and non-immune cells expressing its receptor CXCR3. Previous studies have demonstrated that CXCL10 is involved in myocardial infarction. However, the role of CXCL10 in cardiac microvascular endothelial cell (CMEC) regulation and related mechanisms remains unclear. In this study, we investigated the effects of CXCL10 on the CMEC migration and explored its potential molecular mechanism by wound healing, cell proliferation and viability analysis. Furthermore, migration-related signaling pathways, including FAK, Erk, p38 and Smad, were examined by Western blotting. We found that CXCL10 significantly promotes CMEC migration under normal conditions and during hypoxia/ischemia. However, no significant differences in CMEC proliferation and viability were observed with or without CXCL10 treatment. CXCL10-mediated CMEC migration was greatly blocked by treatment with an anti-CXCR3 antibody. Although CXCL10 treatment promoted phosphorylation and activation of the FAK, Erk, and p38 pathways during hypoxia/ischemia, CXCL10-mediated CMEC migration was significantly blocked by p38 and FAK inhibitors, but not by an Erk inhibitor. Furthermore, CXCL10-mediated FAK activation was suppressed by the p38 inhibitor. These findings indicated that the CXCL10/CXCR3 pathway promotes the migration of CMECs under normal conditions and during hypoxia/ischemia in a proliferation-independent manner, at least in part, through regulation of the p38/FAK pathways.

Original languageEnglish
Pages (from-to)257-265
Number of pages9
JournalExperimental and Molecular Pathology
Volume100
Issue number2
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Endothelial cells
Cell Movement
Endothelial Cells
Ischemia
Cell proliferation
CME-Carbodiimide
Cell Survival
CXCR3 Receptors
Chemical activation
Cell Proliferation
Phosphorylation
Chemokines
Wound Healing
Anti-Idiotypic Antibodies
Western Blotting
Myocardial Infarction
Cells
Antibodies
Hypoxia

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Xia, Jing Bo ; Mao, Cheng Zhou ; Chen, Zhuo Ying ; Liu, Guang Hui ; Wu, Hai Yan ; Zhou, Deng Cheng ; Park, Kyusang ; Zhao, Hui ; Kim, Soo-Ki ; Cai, Dong Qing ; Qi, Xu Feng. / The CXCL10/CXCR3 axis promotes cardiac microvascular endothelial cell migration via the p38/FAK pathway in a proliferation-independent manner. In: Experimental and Molecular Pathology. 2016 ; Vol. 100, No. 2. pp. 257-265.
@article{1eeaf1e1123447278362df381228177b,
title = "The CXCL10/CXCR3 axis promotes cardiac microvascular endothelial cell migration via the p38/FAK pathway in a proliferation-independent manner",
abstract = "CXCL10 is a chemokine with potent chemotactic activity for immune and non-immune cells expressing its receptor CXCR3. Previous studies have demonstrated that CXCL10 is involved in myocardial infarction. However, the role of CXCL10 in cardiac microvascular endothelial cell (CMEC) regulation and related mechanisms remains unclear. In this study, we investigated the effects of CXCL10 on the CMEC migration and explored its potential molecular mechanism by wound healing, cell proliferation and viability analysis. Furthermore, migration-related signaling pathways, including FAK, Erk, p38 and Smad, were examined by Western blotting. We found that CXCL10 significantly promotes CMEC migration under normal conditions and during hypoxia/ischemia. However, no significant differences in CMEC proliferation and viability were observed with or without CXCL10 treatment. CXCL10-mediated CMEC migration was greatly blocked by treatment with an anti-CXCR3 antibody. Although CXCL10 treatment promoted phosphorylation and activation of the FAK, Erk, and p38 pathways during hypoxia/ischemia, CXCL10-mediated CMEC migration was significantly blocked by p38 and FAK inhibitors, but not by an Erk inhibitor. Furthermore, CXCL10-mediated FAK activation was suppressed by the p38 inhibitor. These findings indicated that the CXCL10/CXCR3 pathway promotes the migration of CMECs under normal conditions and during hypoxia/ischemia in a proliferation-independent manner, at least in part, through regulation of the p38/FAK pathways.",
author = "Xia, {Jing Bo} and Mao, {Cheng Zhou} and Chen, {Zhuo Ying} and Liu, {Guang Hui} and Wu, {Hai Yan} and Zhou, {Deng Cheng} and Kyusang Park and Hui Zhao and Soo-Ki Kim and Cai, {Dong Qing} and Qi, {Xu Feng}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.yexmp.2016.01.010",
language = "English",
volume = "100",
pages = "257--265",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "2",

}

The CXCL10/CXCR3 axis promotes cardiac microvascular endothelial cell migration via the p38/FAK pathway in a proliferation-independent manner. / Xia, Jing Bo; Mao, Cheng Zhou; Chen, Zhuo Ying; Liu, Guang Hui; Wu, Hai Yan; Zhou, Deng Cheng; Park, Kyusang; Zhao, Hui; Kim, Soo-Ki; Cai, Dong Qing; Qi, Xu Feng.

In: Experimental and Molecular Pathology, Vol. 100, No. 2, 01.04.2016, p. 257-265.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The CXCL10/CXCR3 axis promotes cardiac microvascular endothelial cell migration via the p38/FAK pathway in a proliferation-independent manner

AU - Xia, Jing Bo

AU - Mao, Cheng Zhou

AU - Chen, Zhuo Ying

AU - Liu, Guang Hui

AU - Wu, Hai Yan

AU - Zhou, Deng Cheng

AU - Park, Kyusang

AU - Zhao, Hui

AU - Kim, Soo-Ki

AU - Cai, Dong Qing

AU - Qi, Xu Feng

PY - 2016/4/1

Y1 - 2016/4/1

N2 - CXCL10 is a chemokine with potent chemotactic activity for immune and non-immune cells expressing its receptor CXCR3. Previous studies have demonstrated that CXCL10 is involved in myocardial infarction. However, the role of CXCL10 in cardiac microvascular endothelial cell (CMEC) regulation and related mechanisms remains unclear. In this study, we investigated the effects of CXCL10 on the CMEC migration and explored its potential molecular mechanism by wound healing, cell proliferation and viability analysis. Furthermore, migration-related signaling pathways, including FAK, Erk, p38 and Smad, were examined by Western blotting. We found that CXCL10 significantly promotes CMEC migration under normal conditions and during hypoxia/ischemia. However, no significant differences in CMEC proliferation and viability were observed with or without CXCL10 treatment. CXCL10-mediated CMEC migration was greatly blocked by treatment with an anti-CXCR3 antibody. Although CXCL10 treatment promoted phosphorylation and activation of the FAK, Erk, and p38 pathways during hypoxia/ischemia, CXCL10-mediated CMEC migration was significantly blocked by p38 and FAK inhibitors, but not by an Erk inhibitor. Furthermore, CXCL10-mediated FAK activation was suppressed by the p38 inhibitor. These findings indicated that the CXCL10/CXCR3 pathway promotes the migration of CMECs under normal conditions and during hypoxia/ischemia in a proliferation-independent manner, at least in part, through regulation of the p38/FAK pathways.

AB - CXCL10 is a chemokine with potent chemotactic activity for immune and non-immune cells expressing its receptor CXCR3. Previous studies have demonstrated that CXCL10 is involved in myocardial infarction. However, the role of CXCL10 in cardiac microvascular endothelial cell (CMEC) regulation and related mechanisms remains unclear. In this study, we investigated the effects of CXCL10 on the CMEC migration and explored its potential molecular mechanism by wound healing, cell proliferation and viability analysis. Furthermore, migration-related signaling pathways, including FAK, Erk, p38 and Smad, were examined by Western blotting. We found that CXCL10 significantly promotes CMEC migration under normal conditions and during hypoxia/ischemia. However, no significant differences in CMEC proliferation and viability were observed with or without CXCL10 treatment. CXCL10-mediated CMEC migration was greatly blocked by treatment with an anti-CXCR3 antibody. Although CXCL10 treatment promoted phosphorylation and activation of the FAK, Erk, and p38 pathways during hypoxia/ischemia, CXCL10-mediated CMEC migration was significantly blocked by p38 and FAK inhibitors, but not by an Erk inhibitor. Furthermore, CXCL10-mediated FAK activation was suppressed by the p38 inhibitor. These findings indicated that the CXCL10/CXCR3 pathway promotes the migration of CMECs under normal conditions and during hypoxia/ischemia in a proliferation-independent manner, at least in part, through regulation of the p38/FAK pathways.

UR - http://www.scopus.com/inward/record.url?scp=84956654695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956654695&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2016.01.010

DO - 10.1016/j.yexmp.2016.01.010

M3 - Article

C2 - 26835911

AN - SCOPUS:84956654695

VL - 100

SP - 257

EP - 265

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 2

ER -